Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.53
-$0.01-1.13%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -47.92% | -24.24% | 13.48% | 18.34% | -7.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -56.90% | -49.96% | -43.37% | -52.38% | -25.30% |
| Operating Income | 56.90% | 49.96% | 43.37% | 52.38% | 25.30% |
| Income Before Tax | 59.55% | 50.33% | 46.20% | 52.09% | 23.01% |
| Income Tax Expenses | -67.50% | -36.54% | -38.30% | -- | 8.11% |
| Earnings from Continuing Operations | 59.56% | 50.32% | 46.20% | 52.06% | 22.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.56% | 50.32% | 46.20% | 52.06% | 22.98% |
| EBIT | 56.90% | 49.96% | 43.37% | 52.38% | 25.30% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 92.28% | 82.58% | 81.55% | 77.70% | 53.36% |
| Normalized Basic EPS | 92.28% | 82.58% | 81.55% | 77.72% | 53.38% |
| EPS Diluted | 92.28% | 82.58% | 81.55% | 77.70% | 53.36% |
| Normalized Diluted EPS | 92.28% | 82.58% | 81.55% | 77.72% | 53.38% |
| Average Basic Shares Outstanding | 423.60% | 185.18% | 191.54% | 115.02% | 65.12% |
| Average Diluted Shares Outstanding | 423.60% | 185.18% | 191.54% | 115.02% | 65.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |